Our Team
Below, you’ll find our leadership and collaborators in action, from the Board of Directors and executive leaders to advisory committees and partners, each contributing essential expertise and guidance to move our work forward.
Board of
Directors
Executive
Committee
Advisory
Committees
Our
Partners
Board of Directors
Our board is composed of a distinguished group of leaders and experts in oncology, research, healthcare, and patient advocacy. Together, they provide strategic guidance, governance, and oversight to ensure CMRG remains at the forefront of multiple myeloma research. With a shared commitment to advancing science and improving patient care, our board plays a crucial role in shaping the future of innovative therapies, clinical advancements, and ensuring that patient needs are at the center of all our efforts.
Darrell White, MD
Chair
Dr. Darrell White is a renowned hematologist at Queen Elizabeth II Health Sciences Centre and a professor of medicine, as well as the Senior Associate Dean in the Faculty of Medicine at Dalhousie University.
Read More
He has held numerous leadership roles in medical education at Dalhousie and the Royal College of Physicians and Surgeons of Canada. His clinical practice and research are dedicated to advancing the treatment of multiple myeloma patients.
Christopher Venner, MD
Vice Chair
Dr. Christopher Venner, a specialist in hematology with expertise in plasma cell dyscrasias, currently practices at BC Cancer Vancouver Centre.
Read More
After completing fellowship training in the UK, he returned to Canada to lead the Myeloma/Plasma Cell Dyscrasias group at the Cross Cancer Institute. His academic focus on clinical trials and the evolution of plasma cell dyscrasia therapies is deeply integrated with his leadership role as Chair of the CMRG Canadian Multiple Myeloma Database initiative and the CMRG clinical trials group.
Darrell White, MD
Chair
Read More
Dr. Darrell White is a renowned hematologist at Queen Elizabeth II Health Sciences Centre and a professor of medicine, as well as the Senior Associate Dean in the Faculty of Medicine at Dalhousie University.
He has held numerous leadership roles in medical education at Dalhousie and the Royal College of Physicians and Surgeons of Canada. His clinical practice and research are dedicated to advancing the treatment of multiple myeloma patients.
Christopher Venner, MD
Vice Chair
Read More
Dr. Christopher Venner, a specialist in hematology with expertise in plasma cell dyscrasias, currently practices at BC Cancer Vancouver Centre. After completing fellowship training in the UK, he returned to Canada to lead the Myeloma/Plasma Cell Dyscrasias group at the Cross Cancer Institute. His academic focus on clinical trials and the evolution of plasma cell dyscrasia therapies is deeply integrated with his leadership role as Chair of the CMRG Canadian Multiple Myeloma Database initiative and the CMRG clinical trials group.